kabutan

PhoenixBio Co.,Ltd.(6190) Summary

6190
TSE Growth
PhoenixBio Co.,Ltd.
437
JPY
-11
(-2.46%)
Aug 13, 3:30 pm JST
2.95
USD
Aug 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
11.0
PBR
1.32
Yield
ー%
Margin Trading Ratio
Stock Price
Aug 13, 2025
Opening Aug 13, 9:00 am
445 JPY 3.01 USD
Previous Close Aug 12
448 JPY 3.02 USD
High Aug 13, 9:41 am
449 JPY 3.03 USD
Low Aug 13, 2:03 pm
432 JPY 2.91 USD
Volume
34,600
Trading Value
0.02B JPY 0.10M USD
VWAP
439.81 JPY 2.98 USD
Minimum Trading Value
43,700 JPY 295 USD
Market Cap
1.78B JPY 0.01B USD
Number of Trades
115
Liquidity & Number of Trades
As of Aug 13, 2025
Liquidity
Mid
1-Year Average
186
1-Year High Feb 25, 2025
13,787
Margin Trading
Date Short Interest Long Margin Positions Ratio
Aug 8, 2025 0 250,000
Aug 1, 2025 1,400 305,600 218.29
Jul 25, 2025 0 336,900
Jul 18, 2025 0 313,000
Jul 11, 2025 0 329,000
Company Profile
PhoenixBio Co., Ltd. is a biotech venture originating from Hiroshima University, specializing in the production of PXB mice with high human hepatocyte replacement rates and contract testing services.
Sector
Services
PhoenixBio, a biotech venture spun off from Hiroshima University, primarily focuses on providing contract testing services for drug development using PXB mice. PXB mice are chimeric mice with livers largely replaced by human hepatocytes, used for predicting human metabolism and researching hepatitis viruses. The company's main services include pharmacokinetic studies, safety tests, and efficacy evaluations for hepatitis drugs. Additionally, PhoenixBio sells fresh human hepatocytes (PXB-cells) obtained from PXB mice. These services play a crucial role in the preclinical stages of new drug development, supporting pharmaceutical companies in their drug discovery research.